{"id":82912,"date":"2025-07-22T10:14:08","date_gmt":"2025-07-22T10:14:08","guid":{"rendered":"https:\/\/www.europesays.com\/us\/82912\/"},"modified":"2025-07-22T10:14:08","modified_gmt":"2025-07-22T10:14:08","slug":"latent-labs-launches-web-based-ai-model-to-democratize-protein-design","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/82912\/","title":{"rendered":"Latent Labs launches web-based AI model to democratize protein design"},"content":{"rendered":"

About six months after coming out of stealth with $50 million<\/a> in funding, Latent Labs has released a web-based AI model for programming biology.<\/p>\n

Latent Labs model has \u201cachieved state-of-the-art on different metrics\u201d when testing the proteins it developed in a physical lab, according to Latent Labs CEO and founder Simon Kohl, a scientist who previously co-led DeepMind\u2019s AlphaFold\u2019s protein design team. State-of-the-art, or SOTA, is a term often used in the AI field that represents the industry\u2019s best performance to date on a specific task.<\/p>\n

\u201cWe have computational ways of assessing how good the designs are,\u201d he told TechCrunch, adding that a high percentage of proteins the model creates will be viable when tested in the lab.<\/p>\n

The company\u2019s foundational biology model, known as LatentX, enables academic institutions, biotech startups, and pharmaceutical companies to design novel proteins directly in their browser using natural language.<\/p>\n

LatentX goes beyond what\u2019s found in nature, creating entirely new molecule designs like nanobodies and antibodies with precise atomic structures. This approach can help develop new therapeutics at much faster rare.<\/p>\n

This ability to design entirely new proteins is what distinguishes LatentX from the AlphaFold, according to Kohl.<\/p>\n

\u201cAlpha fold is a model for protein structure prediction. So it allows you to visualize existing structures, but it doesn\u2019t, it doesn\u2019t let you generate new proteins,\u201d he said. <\/p>\n

Techcrunch event<\/p>\n

\n\t\t\t\t\t\t\t\t\tSan Francisco
\n\t\t\t\t\t\t\t\t\t\t\t\t\t|
\n\t\t\t\t\t\t\t\t\t\t\t\t\tOctober 27-29, 2025\n\t\t\t\t\t\t\t<\/p>\n

In contrast to AI-driven drug discovery companies like Xaira<\/a>, Recursion<\/a> or DeepMind spinout Isomorphic Labs<\/a>, which focus on developing proprietary medicines, Latent Labs\u2019 business model involves licensing its model for use by external organizations. <\/p>\n

\u201cNot every company is in a position to build their own AI models, to have their own AI infrastructure, and to have their own AI teams,\u201d Kohl said.<\/p>\n

While LatentX is available for free, Kohl said the company intends to eventually charge for advanced features and capabilities as they\u2019re introduced.<\/p>\n

Other companies providing open-sourced AI foundational models for drug discovery include Chai Discovery and EvolutionaryScale<\/a>.<\/p>\n

Latent Labs is backed by Radical Ventures, Sofinnova Partners, Google\u2019s Chief Scientist Jeff Dean, Anthropic\u2019s CEO Dario Amodei and Eleven Labs CEO Mati Staniszewski.<\/p>\n","protected":false},"excerpt":{"rendered":"About six months after coming out of stealth with $50 million in funding, Latent Labs has released a…\n","protected":false},"author":3,"featured_media":82913,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[21748,56323,158,67,132,68],"class_list":{"0":"post-82912","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-technology","8":"tag-deepmind","9":"tag-latent-labs","10":"tag-technology","11":"tag-united-states","12":"tag-unitedstates","13":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114896363528123317","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/82912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=82912"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/82912\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/82913"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=82912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=82912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=82912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}